(redirected from Factor X deficiency)
Also found in: Dictionary, Thesaurus, Medical, Financial, Encyclopedia.


An event, circumstance, influence, or element that plays a part in bringing about a result.

A factor in a case contributes to its causation or outcome. In the area of Negligence law, the factors, or chain of causation, are important in determining whether liability ensues from a particular action done by the defendant.

West's Encyclopedia of American Law, edition 2. Copyright 2008 The Gale Group, Inc. All rights reserved.


n. 1) a salesman who sells in his/her own name on behalf of others, taking a commission for services. 2) something that contributes to the result.

Copyright © 1981-2005 by Gerald N. Hill and Kathleen T. Hill. All Right reserved.


1 a mercantile agent. An agent who is in the ordinary course of business entrusted with goods or documents of title representing goods with a view to their sale. A factor has a lien over goods entrusted to him; this lien covers any claims he may have against his principal arising out of the agency. Most factors will be mercantile agents (and have the powers of such) for the purposes of the Factors Act 1889. Under this Act, in certain circumstances a factor may pass a good title to goods entrusted to him.
2 an institution to whom a company assigns its book debts (see FACTORING).
3 in Scotland a landlord or superior's agent.
Collins Dictionary of Law © W.J. Stewart, 2006
References in periodicals archive ?
Plasma protein therapies company Bio Products Laboratory Limited (BPL) announced on Wednesday the submission of its supplemental Biologics License Application (BLA) with the US Food and Drug Administration (FDA) for Coagadex for prophylactic treatment of hereditary factor X deficiency.
Acquired factor X deficiency is the most common coagulation factor deficiency identified in AL amyloidosis and it occurs presumably as a result of adsorption of factor X to amyloid deposits.
Coagadex is Bio Products Laboratory Limited's first and only US FDA-approved product to treat hereditary factor X deficiency and is the only factor X concentrate available in the US, was approved by the US Food and Drug Administration (FDA) on 20 October 2015.
Factor X deficiency was found in 8 families (n=16), 4.0% of the total; one family of the factor X deficient patients was diagnosed after a female baby was delivered with severe CNS bleeding and was found to have <I% factor X activity.